

REMARKS


Claim 29 is being amended to correct an inadvertent error in it. Instead of reading  $\text{CH}(\text{C}_2\text{-C}_4 \text{ alkyl})_6$ ; it now reads  $\text{CH}(\text{C}_2\text{-C}_4 \text{ alkyl})_2$ . No new matter is being introduced.

The various paragraphs in the Specification are being amended to correct two inadvertent errors. One such error is the error corrected in Claim 29, namely changing from  $\text{CH}(\text{C}_2\text{-C}_4 \text{ alkyl})_6$  to  $\text{CH}(\text{C}_2\text{-C}_4 \text{ alkyl})_2$ . The other inadvertent error is correcting the name of DEET from DEED. The other amendments to the Specification are attempts to bring into USPTO desired format trademarked names in the Specification. The trademarks are being capitalized and a generic description is being added. No new matter is being added.

The Third Information Disclosure Statement being filed herewith contains documents disclosed in a European Search Report for the related European patent application. These documents were not cited in previous Search Reports. This Third Information Disclosure Statement is being filed prior to the first Office Action so no fee is due. Should a fee be due, Applicants authorizes the Commissioner to charge all fees due to Deposit Account 19-0134.

Respectfully submitted,

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080  
(862) 778-7922

  
David L. Marks  
Attorney for Applicants  
Reg. No. 37,881

Date: August 11, 2005